Motus GI Holdings, Inc., a medical technology company focused on enhancing endoscopic outcomes, has announced that it has secured clearance from the U.S. Food and Drug Administration (FDA) for its new Pure-Vu EVS Gastro and Gen 4 Colon system. This clearance paves the way for the company to tap into the upper gastrointestinal (GI) market, addressing the needs of patients with upper GI bleeds, a condition with high mortality rates. The new Pure-Vu systems offer significant improvements over previous models, aiming to provide better visualization in both the upper and lower GI tracts. These advancements include a more powerful suction…
Author: Abhay Panchal
Microsoft and Google have recently introduced new features for their healthcare cloud products, aiming to consolidate data from diverse sources such as EHRs, labs, revenue cycles, and more. This integration will enable healthcare organizations to derive insights from various datasets or establish standardized processes. Key Points:
American patients are divided regarding their comfort with the application of artificial intelligence (AI) in their healthcare experiences. A survey conducted by Propeller Insights on behalf of Carta Healthcare revealed the following:
The gastroenterology industry is witnessing rapid advancements with the integration of artificial intelligence and innovative technologies, offering specialists novel methods to care for and treat patients. Here are five groundbreaking GI-industry devices:
An app-based digital therapeutic has shown significant efficacy in reducing symptoms and enhancing the quality of life, work productivity, and health literacy among patients with irritable bowel syndrome (IBS). These findings are from the ColoFuture Study, presented at the UEG Week 2023. Key Findings:
In this month’s column, I highlight three topics that are highly relevant to endoscopy clinical practice: colon polyp sizing, Helicobacter pylori’s relationship with gastric cancer and large nonpedunculated polyps. Although pathologists report the size of colon polyps resected during colonoscopy, the accuracy of such size reporting is questionable. In this study, investigators showed that due to factors such as piecemeal resection, only 60% of polyps sent to pathology can be measured, and of those that are measured, shrinkage of polyp size occurs in almost 25% of the specimens. The majority of the results showing a reduction in gastric incidents after…
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in early cancer detection, has unveiled the significant findings of its ColoFuture Study. The study was initially set for presentation at the 4th International Conference on Gastroenterology in Paris but was rescheduled. Despite the change, Mainz Biomed decided to release the results as per the original conference timeline. Key Findings:
Alimentiv Inc., a prominent Contract Research Organization specializing in GI-related therapeutics, has announced the inclusion of new scientific advisors to its scientific advisory board. These advisors are globally acknowledged experts in designing and conducting clinical research in Inflammatory Bowel Disease (IBD). Their significant contributions have been pivotal in advancing the development of innovative IBD therapies and enhancing patient outcomes. Highlighted Advisors: Dr./Prof. Remo Panaccione: A Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary, Alberta, Canada. He is also the Dean of MD Admissions and Director of the IBD Fellowship Program. Dr.…
People with precancerous colonic lesions exhibit significant differences in their gut microbiome compared to the general population, even up to 5 years before the development of these lesions. This insight comes from a comprehensive 22-year analysis conducted by the Dutch Microbiome Project cohort study. The study suggests that the gut microbiota might play a role in the onset of colorectal lesions and cancer. Ranko Gacesa, PhD, from the Department of Gastroenterology, University of Groningen, Netherlands, presented the findings at the United European Gastroenterology (UEG) Week 2023. He emphasized the potential of gut bacteria to enhance the efficacy of noninvasive fecal…
Illumina has provided further details regarding the European Commission’s (EC) directive to reverse its acquisition of Grail, a company that developed a blood test for multiple cancer screenings. Illumina acquired Grail for $8 billion in 2021 without the EC’s approval. The key points from the disclosure are: